Biomarker characterization in endometrial cancer in Europe: first survey data analysis from 69 pathological academic and hospital labs.

IF 4.4 Q1 PATHOLOGY
PATHOLOGICA Pub Date : 2024-02-01 DOI:10.32074/1591-951X-926
Angela Santoro, Emma Bragantini, Francesca Castiglione, Raji Ganesan, Xavier Matias-Guiu, Milo Frattini, Valerio Gallotta, Pablo Garcia, Yatish Pattni, Julia Tsiampali-Laprell, Brigitte Bisaro, Mattia Barbareschi, Gian Franco Zannoni
{"title":"Biomarker characterization in endometrial cancer in Europe: first survey data analysis from 69 pathological academic and hospital labs.","authors":"Angela Santoro, Emma Bragantini, Francesca Castiglione, Raji Ganesan, Xavier Matias-Guiu, Milo Frattini, Valerio Gallotta, Pablo Garcia, Yatish Pattni, Julia Tsiampali-Laprell, Brigitte Bisaro, Mattia Barbareschi, Gian Franco Zannoni","doi":"10.32074/1591-951X-926","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Endometrial carcinoma (EC) is the commonest gynecological cancer affecting women in Western populations. To predict patient risk, the 2020 edition of the World Health Organization (WHO) Classification of Tumors of the Female Genital Tract stressed the importance of integrated histo-molecular classification of the disease. This survey analysis poses attention on the most frequently used immunohistochemical and molecular markers adopted in daily categorization of ECs in European laboratories.</p><p><strong>Methods: </strong>We analyzed data collected through questionnaires administered to 40 Italian, 20 Spanish, 3 Swiss and 6 United Kingdom (UK) laboratories. We collected information regarding daily practice in EC evaluation, specifically concerning mismatch repair status (MMR) and microsatellite instability (MSI). Summary and descriptive statistical analyses were carried out to evaluate the current practice of each laboratory.</p><p><strong>Results: </strong>The results show that MMR status is mainly evaluated by using immunohistochemistry (IHC) on most EC samples. The most frequent approach for the analysis of MMR status is IHC of four proteins (PMS2, MSH6, MSH2, MLH1). MSI analysis by molecular methods is uncommon but useful as a supplemental tool in specific conditions. MLH1 promoter hypermethylation and BRAF V600 mutations analysis are performed in case of negative expression of MLH1/PMS2. Other markers (mainly p53 followed by POLE and PTEN) are investigated in particular in Spain and Switzerland in a consistent number of cases.</p><p><strong>Conclusion: </strong>Guidelines consultation and standardization of laboratory procedures are efficient means for EC prognostic risk stratification and improving the quality of care.</p>","PeriodicalId":45893,"journal":{"name":"PATHOLOGICA","volume":null,"pages":null},"PeriodicalIF":4.4000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10938279/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PATHOLOGICA","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32074/1591-951X-926","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Endometrial carcinoma (EC) is the commonest gynecological cancer affecting women in Western populations. To predict patient risk, the 2020 edition of the World Health Organization (WHO) Classification of Tumors of the Female Genital Tract stressed the importance of integrated histo-molecular classification of the disease. This survey analysis poses attention on the most frequently used immunohistochemical and molecular markers adopted in daily categorization of ECs in European laboratories.

Methods: We analyzed data collected through questionnaires administered to 40 Italian, 20 Spanish, 3 Swiss and 6 United Kingdom (UK) laboratories. We collected information regarding daily practice in EC evaluation, specifically concerning mismatch repair status (MMR) and microsatellite instability (MSI). Summary and descriptive statistical analyses were carried out to evaluate the current practice of each laboratory.

Results: The results show that MMR status is mainly evaluated by using immunohistochemistry (IHC) on most EC samples. The most frequent approach for the analysis of MMR status is IHC of four proteins (PMS2, MSH6, MSH2, MLH1). MSI analysis by molecular methods is uncommon but useful as a supplemental tool in specific conditions. MLH1 promoter hypermethylation and BRAF V600 mutations analysis are performed in case of negative expression of MLH1/PMS2. Other markers (mainly p53 followed by POLE and PTEN) are investigated in particular in Spain and Switzerland in a consistent number of cases.

Conclusion: Guidelines consultation and standardization of laboratory procedures are efficient means for EC prognostic risk stratification and improving the quality of care.

欧洲子宫内膜癌的生物标记特征:来自 69 个病理学术实验室和医院实验室的首次调查数据分析。
简介子宫内膜癌(EC)是西方女性最常见的妇科癌症。为预测患者风险,世界卫生组织(WHO)2020 年版《女性生殖道肿瘤分类》强调了对该疾病进行组织-分子综合分类的重要性。本调查分析报告关注欧洲实验室在对EC进行日常分类时最常用的免疫组化和分子标记物:我们分析了通过向 40 家意大利实验室、20 家西班牙实验室、3 家瑞士实验室和 6 家英国实验室发放调查问卷收集到的数据。我们收集了有关EC评估日常实践的信息,特别是有关错配修复状态(MMR)和微卫星不稳定性(MSI)的信息。我们进行了汇总和描述性统计分析,以评估各实验室的现行做法:结果表明,大多数欧共体样本主要通过免疫组化(IHC)来评估MMR状态。最常见的 MMR 状态分析方法是对四种蛋白(PMS2、MSH6、MSH2、MLH1)进行 IHC 分析。通过分子方法进行 MSI 分析并不常见,但在特定情况下可作为补充工具。在 MLH1/PMS2 阴性表达的情况下,可进行 MLH1 启动子高甲基化和 BRAF V600 突变分析。其他标记物(主要是 p53,其次是 POLE 和 PTEN)的检测在西班牙和瑞士的病例中数量一致:结论:指南咨询和实验室程序标准化是欧共体预后风险分层和提高护理质量的有效手段。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
PATHOLOGICA
PATHOLOGICA PATHOLOGY-
CiteScore
5.90
自引率
5.70%
发文量
108
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信